JNJ 1013

Key Product Details

Product Description

JNJ 1013 is a potent interleukin 1 receptor associated kinase 1 (IRAK1) Degrader (PROTAC^®; DC₅₀ = 3 nM; D_max = 96%). In ABC DLBCL cell lines with MyD88 L265P mutation, JNJ 1013 potently inhibits IRAK1 downstream signaling pathways, induces apoptosis, and shows strong anti-proliferative effects.

PROTAC^® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Product Specifications for JNJ 1013

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for JNJ 1013

The following data is based on the product molecular weight 878.06.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.14 mL	5.69 mL	11.39 mL
5 mM	0.23 mL	1.14 mL	2.28 mL
10 mM	0.11 mL	0.57 mL	1.14 mL
50 mM	0.02 mL	0.11 mL	0.23 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Fu Discovery of highly potent and selective IRAK1 Degraders to probe scaffolding functions of IRAK1 in ABC DLBCL. J.Med.Chem. 2021 PMID: 34279092

Product Documents for JNJ 1013